2180 Calumet Street, Clearwater, Florida 33735www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Restoring Vascular Health … Naturally
Clinical Results of a Study in Chronic
Ischemic Heart Disease
CIRCULAT®
22180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Chronic Ischemic Heart Disease
A common serious complication is damage to blood vessels in patients with diabetes, leading to decreased blood flow to the heart and results in pain of angina pectoris and heart attacks.
Cardiac ischemia (angina chronic complications of diabetes) occurs (only in USA) at 6.6 million patients a year, despite the use of established drugs for angina pectoris and some modern surgical procedures - stents, angioplast, etc.
Obviously, the overall disease burden reflects the many limitations of current therapy, as medication for angina pectoris are only partially effective, with a high morbidity and mortality from invasive procedures.
Almost 2 million people each year continue to suffer from cardiac ischemia and angina attacks, even with current interventions and therapies to optimize revascularization. The American Hearth Association in its statistics published in USA there are 8.5 million heart patients and 10.2 million suffer from angina.
According to the WHO World Atlas, heart disease and strokes kill 17 million people each year, approximately 29.3% of deaths worldwide. Nearly 40% is specifically for ischemic heart disease.
32180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
CIRCULAT®Study
in Chronic Ischemic Heart
Disease
42180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Background: Endothelial Damage
Normal Artery Artery Narrowed byAtherosclerotic Plaque
Endothelium
Smooth Muscle
Smooth Muscle Cells
MacrophagesChanged inFoam Cells
Lipids, Calciumand Cellular Debris
Fibrous Layer
Endothelial Damage
EndothelialDisfunction
Mechanical Stress
Hypertension
Vasoconstriction
Peripheral-Vascular Resistance
52180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
GSPECT Cardio-Diagnostic Imaging
Sorce: www.yale.edu/imaging
62180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Treatment study of chronic ischemic heart disease with complex herbal formulation
CIRCULAT®
- Researchers: Roberto Guzmán, José Olalde, Francis Améndola, Oswaldo del Castillo -
Results: There was good response to therapy in 85% of the sample (p ≤ 6.104 e-05,% = 99.9999, determined by Wilcoxon). No patients suffered adverse effects or died
during the study period.
Examples of Case StudiesIncluding GSPECT Image Evidence
72180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 1
GSPECT image
Chronic Ischemic Heart Disease1 year treatment
68 years old male patient, with significant three vessel coronary artery obstruction disease. Indications of surgical myocardium revascularization were rejected. Entered study protocol on 04/29/2009 due to clinical symptoms (FC II Dyspnea on exertion). On such date a Cardiac SPECT is performed and patient commences CIRCULAT®
treatment. Patient presents satisfactory clinical evolution, remaining cardiovascularlyasymptomatic from the second month of treatment. Cardiac SPECT control,
performed on 09/26/2009, showed improvements of the anterior-apical perfusion, while showing the ventriculography study revealed a left ventricle ejection fraction increase (34% to 45%). Left Ventricle Perfusion Defect (PD) during studied period
with CIRCULAT® treatment dropped from 40% to 35%.
82180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 2
Functional Capacity Time (sec.)Functional Capacity Test not done
due physical limitations
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
78 years old female patient, diagnosed with chronic ischemic cardiopathy(previous non ‘Q’ wave lateral myocardial infarction.) with stable FC II (NYHA)
exertion angina diagnosis; cardiac SPECT was performed under pharmacological stress and CIRCULAT® treatment was started on 05/13/2009. A satisfactory clinical evolution was observed; with disappearance of angina 90
days after treatment’s beginning. Control Cardiac SPECT’s were performed 10/28/2009 and 07/07/2010, showing myocardial perfusion improvements in lateral and inferior walls. Left Ventricle Perfusion Defect (PD) during studied period with CIRCULAT® treatment dropped from 45% to 30% (10/28/2009) to
15% (07/07/2010).
92180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 3
Chronic Ischemic Heart Disease1 year treatment
70 years old male patient, diagnosed with chronic ischemic cardiopathy (stable FC II exertion angina). Cardiac SPECT performed on 05/20/2009 and CIRCULAT® treatment
was started. After 60 days of treatment disappearance of Exertion Angina was observed. Control Cardiac SPECT performed on 10/28/2009 showed improvement of
myocardium perfusion in inferior wall, which remains in control as per Cardiac SPECT performed on 06-16-2010 (one year after treatment’s initiation). Left Ventricle
Perfusion Defect (PD) with CIRCULAT® treatment dropped from 20% to 10 % (10/28/2009). Last SPECT control (06/16/2010) determined the same level of PD (10%).
GSPECT Image
102180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 4
GSPECT Image
Chronic Ischemic Heart Disease6 month treatment
Male 68 yeasr old patient, chronic ischemic cardiopathy previously diagnosed, with two prior hospitalizations due to unstable angina and positive Resistance Test (++) for
myocardium ischemia. Enters clinical study on 06/23/2009 when control Cardiac SPECT is performed and CIRCULAT® treatment commences. After a month,
significant improvement of functional capacity for exercise and reduction in the frequency of angina episodes are reflected. Cardiac SPECT performed on 11/11/2009, showed global perfusion defect decrease, while an increase in ejection fraction (from 44% to 50%) is observed. Left Ventricle Perfusion Defect (PD) during studied period
with CIRCULAT® treatment dropped from 70% to 60% (11/11/2009) to 10% (06/16/2010).
112180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 5
Male 68 yeasr old patient, with chronic ischemic cardiopathy (significant obtrusive artery damage in two vases), enters study with FC II Exertion Angina clinical
symptoms. Cardiac SPECT was performed at the start of treatment with CIRCULAT®(on 05/06/2009). Two months after the start of treatment a very satisfactory clinical
evolution is observed; with disappearance of exertion angina. Control Cardiac SPECT was performed on 10/07/2009, which evidenced important improvement of
myocardium perfusion in inferior and anterior-septal walls. Cardiac SPECT on 07/09/2010 reveals ‘without myocardium perfusion defects’. Patient remains
cardiovascularly asymptomatic. Left Ventricle Perfusion Defect (PD) during studied period with CIRCULAT® treatment dropped from 30% to 25% (07/09/2009) to 0
(07/09/2010).
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
122180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 6
Male 42 years old patient diagnosed with chronic ischemic cardiopathy (previous heart attack in lower side) and Mellitus Diabetes type 2. Enters clinical study with
clinical symptoms of FC II Dyspnea on Exertion (NYHA). A Cardiac SPECT was performed and treatment with CIRCULAT® started on 05/06/2009. After two months of treatment disappearance of Dyspnea on Exertion is observed. Control Cardiac
SPECT was performed on 10/07/2009 revealing increase in myocardium perfusion in inferior lateral wall. Improvement is maintained as demonstrated with cardiac SPECT control performed on 06/09/2010. Patient is currently FC I (NYHA). Left
Ventricle Perfusion Defect (PD) during studied period with CIRCULAT® treatment dropped from 30% to 20%. PD is maintained at the same level (20%) on 06/09/2010.
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
132180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 7
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
61 years old male patient, diagnosed with chronic ischemic cardiopathy (stable FC II Exertion Angina) and positive exertion test for ischemic cardiopathy.
Cardiac SPECT was performed and CIRCULAT®treatment started on 04-29-2009. Satisfactory clinical evolution with improvement
of functional capacity for exercise, in spite that Cardiac SPECT Control performed on 09-16-2009 revealed continuance of perfusion defect (15%) in left ventricle
inferior wall, with a post exertion ejection fraction within normalcy. Left Ventricle Perfusion Defect (PD) during studied period with CIRCULAT®
treatment remained at 15%.
142180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 8
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
57 years old female patient seeks consultation because of FC II (NYHA) exertion Dyspnea with positive (+) exertion test for myocardial ischemia. Enters clinical
study on 07/14/2009, when Cardiac SPECT is performed and CIRCULAT® treatment is started. Patient is cardiovascularly asymptomatic after 30 days of treatment.
Control Cardiac SPECT is performed on 11-11-2009, evidencing front wall (front-apical segment), perfusion improvement. This last is maintained in SPECT
performed after 12 months (07-28-2010). Currently cardiovascularly asymptomatic. Left Ventricle Perfusion Defect (PD) during studied period -with CIRCULAT®
treatment- dropped from 10% to 5%.
152180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 9
Chronic Ischemic Heart Disease1 year treatment
GSPECT Image
58 years old male patient, diagnosed with chronic ischemic cardiopathy (previous infarction in inferior wall?). Patient is cardiovascularly asymptomatic when entering clinical study. Cardiac SPECT is performed and CIRCULAT® treatment is started on
07-14-2009. Control cardiac SPECT’s performed on 11-11-2009 and 08-04-2010 reporting continuance of myocardial perfusion defect (20%) in inferior and high lateral walls is reported. Patient remains asymptomatic. Left Ventricle Perfusion Defect (PD) during studied period -with CIRCULAT® treatment- remained at 20%.
162180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 10
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
74 years old female patient, diagnosed with chronic ischemic cardiopathy (previous inferior myocardial infarction), enters study protocol with exertion angina (FC II)
clinical symptoms and recent hospitalization with unstable angina diagnosis. Cardiac SPECT performed and CIRCULAT® treatment started on 05-13-2009.
Cardiovascularly asymptomatic, after four month treatment. Control Cardiac SPECTperformed on 10-07-2009, where important myocardial perfusion defect
improvements were noticed, diminishing from 60% to 35%. Control SPECT performed on 06-02-2010 reveals further perfusion defect decrease to 20%. Currently
continues to be cardiovascularly asymptomatic (08/04/2010) with same PD (20%).
172180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 11
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
75 years old female patient, diagnosed with chronic ischemic cardiopathy (stable angina, FC II Exertion); and positive exertion test (++) in inferior wall. Cardiac SPECT
was performed and treatment with CIRCULAT® started on 08-12-2009, showing a functional class clinical improvement one month after the start of treatment. After 4
months of treatment compliance there is absence of cardiovascular symptoms. Control Cardiac SPECT was performed on 12-08-2009, where Myocardium perfusion defect
improvement -in inferior and lateral walls- is reported. Post exertion ejection fraction stays normal. Left Ventricle Perfusion Defect (PD) during studied period with
CIRCULAT® treatment dropped from 25% to 15%.
182180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Case Study # 12
GSPECT Image
Chronic Ischemic Heart Disease1 year treatment
Female 53 years old patient enters study with clinical symptoms of exertion DyspneaFC II (NYHA) and positive myocardial ischemia exertion test (+). Cardiac SPECT
performed on 07-14-2009, date of CIRCULAT® treatment start. Initial perfusion defect was 10%. Cardiovascularly asymptomatic one month after start of pharmacological
treatment. Control SPECT performed on 12-02-2009, which reported status as ‘normal’and disappearance of perfusion defect (0%). Yearly control SPECT (08-04-2010)
remains within normal parameters with PD maintained at 0%.
192180 Calumet Street, Clearwater, Florida 33735
www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
Conclusions
Results in the administration of CIRCULAT® have proven to be therapeutically effective, accessible and safe for the treatment of chronic ischemic heart disease
The evidence of the effectiveness of CIRCULAT® was determined by imaging product of the state of science through GSPECT (CT photon emission).
CIRCULAT® is the only known treatment capable of producing oral myocardial reperfusion in patients with chronic ischemic heart disease.
2180 Calumet Street, Clearwater, Florida 33735www.circuforte.com
CIRCULAT® is a Trademark property of CIRCULAT BIOTECH, LLC
For additional information about clinical trialsand CIRCULAT®, please contact us at
CIRCULAT BIOTECH, LLC
2180 Calumet St.
Clearwater, Florida 33735
Dr. José Angel Olalde Rangel, CEO & Founder
Phone: +727-214-1290 / +58-212-945-9925